- Home
- OPK vs VIR Comparison
OPK vs VIR Comparison
Compare OPK & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPK
- VIR
- Stock Information
- Founded
- OPK 2007
- VIR 2016
- Country
- OPK United States
- VIR United States
- Employees
- OPK N/A
- VIR N/A
- Industry
- OPK Biotechnology: Pharmaceutical Preparations
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- OPK Health Care
- VIR Health Care
- Exchange
- OPK Nasdaq
- VIR Nasdaq
- Market Cap
- OPK N/A
- VIR 706.4M
- IPO Year
- OPK 1995
- VIR 2019
- Fundamental
- Price
- OPK $1.35
- VIR $5.65
- Analyst Decision
- OPK Buy
- VIR Strong Buy
- Analyst Count
- OPK 4
- VIR 8
- Target Price
- OPK $2.75
- VIR $30.25
- AVG Volume (30 Days)
- OPK 3.4M
- VIR 1.2M
- Earning Date
- OPK 08-06-2025
- VIR 07-31-2025
- Dividend Yield
- OPK N/A
- VIR N/A
- EPS Growth
- OPK N/A
- VIR N/A
- EPS
- OPK N/A
- VIR N/A
- Revenue
- OPK $689,408,000.00
- VIR $20,861,000.00
- Revenue This Year
- OPK N/A
- VIR N/A
- Revenue Next Year
- OPK $7.80
- VIR $0.62
- P/E Ratio
- OPK N/A
- VIR N/A
- Revenue Growth
- OPK N/A
- VIR N/A
- 52 Week Low
- OPK $1.21
- VIR $4.32
- 52 Week High
- OPK $2.04
- VIR $14.45
- Technical
- Relative Strength Index (RSI)
- OPK 52.54
- VIR 57.21
- Support Level
- OPK $1.33
- VIR $5.20
- Resistance Level
- OPK $1.36
- VIR $6.23
- Average True Range (ATR)
- OPK 0.04
- VIR 0.30
- MACD
- OPK 0.01
- VIR 0.07
- Stochastic Oscillator
- OPK 73.33
- VIR 56.06
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.